CNSP — CNS Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $5.29m
- -$6.72m
- 13
- 54
- 53
- 33
Annual cashflow statement for CNS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.46 | -14 | -15.3 | -18.9 | -14.9 |
| Depreciation | |||||
| Non-Cash Items | 1.29 | 1.72 | 1.54 | 1.01 | 1.44 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.834 | -1.24 | 3.16 | 3.7 | -3.69 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -7.32 | -13.5 | -10.6 | -14.1 | -17.1 |
| Capital Expenditures | -0.018 | -0.006 | -0.004 | -0.004 | -0.004 |
| Purchase of Fixed Assets | |||||
| Cash from Investing Activities | -0.018 | -0.006 | -0.004 | -0.004 | -0.004 |
| Financing Cash Flow Items | -0.045 | 0 | — | — | -0.067 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 14.1 | 4.51 | 15.6 | 4.64 | 23 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.8 | -9.03 | 5.05 | -9.51 | 5.91 |